Printer Friendly

Lonza Acquires Octane Biotech.

Lonza has acquired a controlling stake in Octane Biotech, with the right to acquire full ownership. The increase in equity share will allow Lonza to further develop the technology to support the growing need for scalable autologous manufacturing. Octane Orthobiologics Inc. will maintain exclusivity to a certain subset of orthopedic clinical indications for use in the Cocoon system.

The two companies have been collaborating since 2015 on the development of the Cocoon system, a patient-scale, closed and automated cell-therapy manufacturing system.

Following an intensive joint-development program, the Cocoon system now incorporates the majority of unit operations needed for scalable end-to-end manufacturing of cell therapies including Mesenchymal stem cells (MSC) and Chimeric Antigen ReceptorT cells (CAR-T cells).

In addition, the flexible, disposable cassettes can be modified to accommodate a wide range of autologous cell therapy processes for adherent cells, non-adherent cells and combination products. This advantage provides flexibility in a field that utilizes a variety of cell types and processes.

"This acquisition is a clear message to the market that we are committed to making commercially viable and scalable personalized therapies a reality," said Marc Funk, chief operating officer, Lonza Pharma & Biotech." We are looking to disruptive innovation, including automation to enable our customers to bring these promising therapies to patients."

Timothy Smith, co-founder of Octane Biotech with Ian Grant, said, "As continuing shareholders and directors of Octane Biotech, we welcome the expanded engagement of Lonza to significantly accelerate and reinforce the role of the Cocoon system as a game changer in the autologous cell therapy manufacturing space. Since the inception of the company, the vision of our team has been to bring award-winning innovation to this sector, and we are confi dent that Lonza will excel in enabling these transformative therapies to reach more patients throughout the world."

The Cocoon system is part of Lonza's autologous cell therapy offerings. The company is currently working with customers to integrate the Cocoon manufacturing equipment as a part of their clinical and commercial manufacturing strategy.

Octane Biotech's 24 employees at the current site in Kingston, ON, will continue to support activities as the Cocoon system is further developed. In addition, Lonza's autologous cell therapy group will maintain their support of Cocoon system-related activities from the Maryland R&D site.

COPYRIGHT 2018 Rodman Publishing
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:TOP OF THE NEWS
Publication:Contract Pharma
Date:Nov 1, 2018
Words:376
Previous Article:Teva Seals Deal for NJ HQ.
Next Article:Contract Pharmacal Unveils $40M Expansion Plan.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters